Multiple Myeloma with Biotech Carvykti

Carvykti, developed by Janssen Biotech, is a type of immunotherapy for adult patients with Multiple Myeloma. Through Carvykti therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.

1 Result(s)

Distance

Keck Medicine of USC

1500 San Pablo St.
LOS ANGELES, CA 90033

2223 Miles

Learn more

Details

Inclusions

The Bundled Rate plus Outlier Per Diems includes:

1. Those comprehensive facility services, supplies, and equipment necessary to perform the Bundled Procedure and rendered by PROVIDER 2. Those professional services necessary to perform the Bundled Procedure and rendered by a Physician 3. The treatment of any complication resulting from the performance of the Bundled Procedure 4. The Cost of the CAR T-Cell Product is included in the bundled rate. The Bundled Rate period begins on the day of the prep regime for the scheduled Accarent Procedure and covers up to 15 inpatient days in the hospital. Should the length of stay exceed 15 inpatient days, then per diem outlier payments will be applicable for each subsequent inpatient day. Covered outpatient follow-up services related to the bundled procedure beginning on the day of infusion through 60 calendar days are included in the bundled price.

Exclusions

There are no exclusions.

Candidacy

Candidacy for the bundled procedure will be determined by the Provider.

Multiple Myeloma with Biotech Carvykti

Similar Procedures